NISSEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 711 JPY | -0.14% |
|
+6.28% | +22.59% |
| May. 10 | 7-Eleven Operator Seven & i Selling Nissen to Ci Medical | MT |
| 2023 | Eli Lilly's Experimental Drug Cut Heart Disease Risk Factor by 94% for Almost a Year, Trial Shows | MT |
Valuation
| Fiscal Period: February | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,524 | 2,187 | 2,514 | 2,215 | 2,207 | 2,262 |
| Enterprise Value (EV) 1 | 1,989 | 1,461 | 1,359 | 1,065 | 942.2 | 1,128 |
| P/E ratio | 11.6 x | 11.5 x | 13.2 x | 8.9 x | 8.76 x | 11.5 x |
| Yield | 3.21% | 3.72% | 3.29% | 3.51% | 3.7% | 4.36% |
| Capitalization / Revenue | 0.5 x | 0.43 x | 0.52 x | 0.46 x | 0.44 x | 0.43 x |
| EV / Revenue | 0.4 x | 0.29 x | 0.28 x | 0.22 x | 0.19 x | 0.22 x |
| EV / EBITDA | 5.57 x | 4.16 x | 3.92 x | 2.86 x | 2.57 x | 2.69 x |
| EV / FCF | -26.7 x | 5.43 x | 3.29 x | 5.95 x | 5.92 x | -9 x |
| FCF Yield | -3.74% | 18.4% | 30.4% | 16.8% | 16.9% | -11.1% |
| Price to Book | 0.94 x | 0.79 x | 0.86 x | 0.75 x | 0.68 x | 0.69 x |
| Nbr of stocks (in thousands) | 3,862 | 3,871 | 3,943 | 3,704 | 3,886 | 3,789 |
| Reference price 2 | 653.5 | 565.0 | 637.5 | 598.0 | 568.0 | 597.0 |
| Announcement Date | 5/28/19 | 5/28/20 | 5/27/21 | 5/26/22 | 5/26/23 | 5/30/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: February | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5,021 | 5,081 | 4,829 | 4,837 | 5,058 | 5,224 |
| EBITDA 1 | 357 | 351 | 347 | 373 | 367 | 419 |
| EBIT 1 | 304 | 291 | 293 | 324 | 320 | 300 |
| Operating Margin | 6.05% | 5.73% | 6.07% | 6.7% | 6.33% | 5.74% |
| Earnings before Tax (EBT) 1 | 338 | 292 | 308 | 373 | 349 | 284 |
| Net income 1 | 229 | 197 | 192 | 253 | 244 | 197 |
| Net margin | 4.56% | 3.88% | 3.98% | 5.23% | 4.82% | 3.77% |
| EPS 2 | 56.54 | 49.12 | 48.14 | 67.18 | 64.81 | 51.77 |
| Free Cash Flow 1 | -74.38 | 269.1 | 413 | 179 | 159.1 | -125.4 |
| FCF margin | -1.48% | 5.3% | 8.55% | 3.7% | 3.15% | -2.4% |
| FCF Conversion (EBITDA) | - | 76.67% | 119.02% | 47.99% | 43.36% | - |
| FCF Conversion (Net income) | - | 136.61% | 215.1% | 70.75% | 65.22% | - |
| Dividend per Share 2 | 21.00 | 21.00 | 21.00 | 21.00 | 21.00 | 26.00 |
| Announcement Date | 5/28/19 | 5/28/20 | 5/27/21 | 5/26/22 | 5/26/23 | 5/30/24 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: February | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,387 | 2,365 | 1,402 | 1,293 | 2,515 | 1,334 | 1,213 | 2,501 | 1,384 | 1,463 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 126 | 162 | 148 | 88 | 162 | 107 | 37 | 81 | 118 | 117 |
| Operating Margin | 5.28% | 6.85% | 10.56% | 6.81% | 6.44% | 8.02% | 3.05% | 3.24% | 8.53% | 8% |
| Earnings before Tax (EBT) 1 | 160 | 259 | 118 | 88 | 158 | 109 | 13 | 72 | 116 | 119 |
| Net income 1 | 109 | 180 | 78 | 60 | 106 | 74 | 14 | 53 | 79 | 81 |
| Net margin | 4.57% | 7.61% | 5.56% | 4.64% | 4.21% | 5.55% | 1.15% | 2.12% | 5.71% | 5.54% |
| EPS 2 | 27.70 | 48.14 | 21.23 | 16.35 | 57.52 | 19.68 | 3.900 | 14.17 | 20.78 | 21.57 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/15/20 | 10/13/21 | 1/14/22 | 7/13/22 | 10/13/22 | 1/13/23 | 7/13/23 | 10/13/23 | 1/12/24 | 7/10/24 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: February | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 535 | 726 | 1,155 | 1,150 | 1,265 | 1,134 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -74.4 | 269 | 413 | 179 | 159 | -125 |
| ROE (net income / shareholders' equity) | 8.68% | 7.13% | 6.67% | 8.62% | 8.02% | 6.14% |
| ROA (Net income/ Total Assets) | 4.39% | 4.2% | 4.09% | 4.58% | 4.52% | 4.12% |
| Assets 1 | 5,219 | 4,690 | 4,695 | 5,527 | 5,403 | 4,786 |
| Book Value Per Share 2 | 697.0 | 714.0 | 743.0 | 794.0 | 836.0 | 865.0 |
| Cash Flow per Share 2 | 306.0 | 331.0 | 427.0 | 438.0 | 446.0 | 392.0 |
| Capex 1 | 14 | 7 | 12 | 11 | 4 | 37 |
| Capex / Sales | 0.28% | 0.14% | 0.25% | 0.23% | 0.08% | 0.71% |
| Announcement Date | 5/28/19 | 5/28/20 | 5/27/21 | 5/26/22 | 5/26/23 | 5/30/24 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +22.59% | 17.06M | |
| +13.02% | 6.78B | |
| -32.02% | 1.45B | |
| -14.59% | 1.14B | |
| -27.26% | 936M | |
| +31.79% | 495M | |
| +16.91% | 467M | |
| -22.41% | 431M | |
| -46.05% | 393M | |
| -37.98% | 345M |
- Stock Market
- Equities
- 6543 Stock
- Financials Nissen Inc.
